Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $19.73 Consensus Target Price from Brokerages

by · The Cerbat Gem

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) have received an average recommendation of “Hold” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $19.7273.

Several analysts have issued reports on BCYC shares. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $11.00 target price (down previously from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a report on Friday, October 31st. Citizens Jmp upped their price objective on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research note on Friday, October 31st. Truist Financial initiated coverage on shares of Bicycle Therapeutics in a report on Monday, November 24th. They set a “hold” rating and a $10.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd.

Get Our Latest Report on BCYC

Bicycle Therapeutics Stock Up 4.1%

BCYC opened at $7.08 on Friday. The business’s fifty day simple moving average is $7.06 and its 200 day simple moving average is $7.45. Bicycle Therapeutics has a 52 week low of $6.03 and a 52 week high of $15.47. The stock has a market cap of $491.14 million, a PE ratio of -1.96 and a beta of 1.52.

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. The firm had revenue of $11.73 million during the quarter, compared to analysts’ expectations of $8.25 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%. As a group, equities analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Long Focus Capital Management LLC increased its stake in Bicycle Therapeutics by 138.2% in the 1st quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock worth $10,984,000 after purchasing an additional 750,661 shares during the period. Armistice Capital LLC boosted its stake in shares of Bicycle Therapeutics by 21.7% during the first quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock valued at $22,685,000 after purchasing an additional 476,000 shares during the period. Millennium Management LLC grew its holdings in shares of Bicycle Therapeutics by 156.5% in the first quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock worth $3,850,000 after purchasing an additional 276,671 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Bicycle Therapeutics in the first quarter worth $214,000. Finally, Woodline Partners LP bought a new stake in Bicycle Therapeutics during the 1st quarter valued at $3,088,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.

Featured Articles